Eidos Therapeutics Inc. (EIDX)’s Financial Results Comparing With Ionis Pharmaceuticals Inc. (NASDAQ:IONS)

Eidos Therapeutics Inc. (NASDAQ:EIDX) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eidos Therapeutics Inc. N/A 0.00 43.58M -1.14 0.00
Ionis Pharmaceuticals Inc. 752.47M 12.41 365.62M 0.51 137.95

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Eidos Therapeutics Inc. and Ionis Pharmaceuticals Inc.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Eidos Therapeutics Inc. 0.00% 0% 0%
Ionis Pharmaceuticals Inc. 48.59% -31.1% -8.7%

Liquidity

28.1 and 28.1 are the respective Current Ratio and a Quick Ratio of Eidos Therapeutics Inc. Its rival Ionis Pharmaceuticals Inc.’s Current and Quick Ratios are 8 and 8 respectively. Eidos Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Ionis Pharmaceuticals Inc.

Analyst Ratings

Ratings and Recommendations for Eidos Therapeutics Inc. and Ionis Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Eidos Therapeutics Inc. 0 0 2 3.00
Ionis Pharmaceuticals Inc. 0 2 1 2.33

Eidos Therapeutics Inc. has a 33.32% upside potential and an average price target of $31.33. Competitively Ionis Pharmaceuticals Inc. has an average price target of $68.33, with potential upside of 2.67%. The results from earlier shows that analysts view suggest that Eidos Therapeutics Inc. seems more appealing than Ionis Pharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both Eidos Therapeutics Inc. and Ionis Pharmaceuticals Inc. are owned by institutional investors at 31.5% and 89.1% respectively. Insiders owned 61.8% of Eidos Therapeutics Inc. shares. Competitively, insiders own roughly 0.2% of Ionis Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eidos Therapeutics Inc. 6.3% 50.7% 26.03% 32.28% 0% 33.72%
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%

For the past year Eidos Therapeutics Inc. has stronger performance than Ionis Pharmaceuticals Inc.

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.